MRNA - What's Going On With Moderna Stock On Monday? | Benzinga
Recently, on clinicaltrials.gov, Merck & Co Inc (NYSE:MRK) posted a new trial of Moderna Inc’s (NASDAQ:MRNA) V940, an individualized neoantigen therapy (INT), plus pembrolizumab for locally resectable advanced cutaneous squamous cell carcinoma (LA cSCC).
Phase 2 has three arms V940 plus pembrolizumab given as neoadjuvant and adjuvant treatment with standard of care (SOC), standard of care (surgical resection with/without adjuvant radiation therapy (RT) only at investigator’s discretion) and pembrolizumab monotherapy given as neoadjuvant and adjuvant treatment with SOC.
This phase will assess the safety and efficacy of V940 in combination with pembrolizumab as neoadjuvant and adjuvant therapy in participants with resectable LA cSCC compared to standard-of-care SOC only.
The primary hypothesis is that V940 plus pembrolizumab with ...